Should we treat high LDL cholesterol in 'healthy' elderly individuals?

Affiliations

Jane K Stock. Atherosclerosis. 2021 Jan.

. 2021 Jan:317:50-51.

doi: 10.1016/j.atherosclerosis.2020.11.029. Epub 2020 Dec 4.

¹ European Atherosclerosis Society, World Trade Center Göteborg, Mässans Gata 10, SE-412 51, Göteborg, Sweden. Electronic address: office@eas-society.org.

No abstract available

Keywords: ASCVD; Cholesterol; Elderly; Individual; LDL.

Comment in

It's time to stop the nonsense of withholding lipid lowering therapy on account of age.
Spence JD. Spence JD. Atherosclerosis. 2021 Apr;323:56. doi: 10.1016/j.atherosclerosis.2021.01.023. Epub 2021 Feb 4. Atherosclerosis. 2021. PMID: 33583573 No abstract available.
Benefits and harms of LDL-cholesterol-lowering therapy in older people must be established through valid and clinically relevant evidence.
Suadoni MT. Suadoni MT. Atherosclerosis. 2021 Apr;323:57-58. doi: 10.1016/j.atherosclerosis.2021.02.001. Epub 2021 Feb 6. Atherosclerosis. 2021. PMID: 33589133 No abstract available.
Reply to: "It's time to stop the nonsense of withholding lipid lowering therapy on account of age" and "The evidence around safe and effective LDL cholesterol-lowering therapy in elderly individuals demands validity and clinical relevance".
Stock JK. Stock JK. Atherosclerosis. 2021 Apr;323:59-60. doi: 10.1016/j.atherosclerosis.2021.03.005. Epub 2021 Mar 15. Atherosclerosis. 2021. PMID: 33762114 No abstract available.